fludarabine and thiotepa

fludarabine has been researched along with thiotepa in 72 studies

Research

Studies (72)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (20.83)29.6817
2010's32 (44.44)24.3611
2020's25 (34.72)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV1
Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Colombo, AA; Lazzarino, M; Malcovati, L; Pagnucco, G; Varettoni, M1
Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F1
Abonour, R; Logan, TF; Nelson, RP1
Caenazzo, L; Calore, E; Cesaro, S; De Silvestro, G; Destro, R; Gazzola, MV; Marson, P; Messina, C; Pillon, M; Varotto, S; Zanesco, L1
Amin, K; Chen, YH; Cheung, T; Devine, S; Hoffman, R; Jessop, E; Maynard, V; Peace, D; Ravandi, F; Sosman, J; Stock, W; van Besien, K; Vijayakumar, S; Wickrema, A; Yassine, M1
Byun, JH; Hong, YS; Kim, CC; Lee, JW; Lee, MA; Min, WS; Park, JN; Roh, SY; Shim, BY; Song, CW1
Alessandrino, EP; Bernasconi, P; Caldera, D; Colombo, AA; Lazzarino, M; Malcovati, L; Montanari, F; Troletti, D; Vanelli, L; Varettoni, M1
Bernardi, M; Bregni, M; Corradini, P; Deola, S; Fleischhauer, K; Guggiari, E; Lunghi, F; Mazzi, B; Monari, M; Peccatori, J; Pescarollo, A; Re, F; Scaramuzza, S; Servida, P; Setola, E1
Arbelaez, JE; Bacigalupo, A; Bregni, M; Carnevalli, E; Corradini, P; Davoli, M; De Fabritiis, P; Di Bartolomeo, P; Locasciulli, A; Majolino, I; Musso, M; Narni, F; Olivieri, A; Pogliani, L; Ruscio, C; Scimè, R; Selleri, C1
Allwinn, R; Beske, F; Klingebiel, T; Kriener, S; Lehrnbecher, T; Modrow, S; Schmidt, H; Schwabe, D; Sörensen, J1
Bertz, H; Finke, J; Grüllich, C; Müller, CI; Spyridonidis, A1
Bernardo, ME; Caocci, G; Comoli, P; Cugno, C; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Merli, P; Piras, E; Vacca, A; Zecca, M1
Cano, P; Champlin, RE; Ciurea, SO; de Lima, M; Fernandez-Vina, M; Gajewski, J; Giralt, S; Jones, RB; Kebriaei, P; Korbling, M; McMannis, J; Pesoa, S; Qazilbash, M; Qureshi, S; Rondon, G; Saliba, R; Shpall, EJ; Worth, LL1
Fujioka, T; Ikegame, K; Inoue, T; Kaida, K; Kato, R; Kim, EH; Nakata, J; Ogawa, H; Okada, M; Soma, T; Tamaki, H; Taniguchi, K; Yoshihara, S1
Cassuto, JP; Cluzeau, T; De Matteis, M; Gratecos, N; Mannone, L; Mounier, N; Raynaud, S; Sirvent, A; Thyss, A; Ticchioni, M1
Abraham, A; Kasow, KA; Morales-Tirado, VM; Persons, DA; Riberdy, JM; Shurtleff, SA; Wichlan, D1
Bassett, R; Champlin, RE; Chan, KW; Ciurea, SO; Couriel, DR; de Lima, M; Fernandez-Vina, M; Hamerschlak, N; Hosing, CM; Jones, RB; Karduss Aurueta, AJ; Kebriaei, P; McMannis, J; Nieto, Y; Petropoulos, D; Qazilbash, M; Rondon, G; Saliba, RM; Sharma, M; Shpall, EJ; Worth, LL1
Anasetti, C; Cooley, S; Curtsinger, J; Defor, T; Devine, S; DiPersio, J; Drobyski, W; Farag, S; Fehniger, TA; Haagenson, M; Miller, J; Porter, D; Waller, EK; Weisdorf, D1
Barrenetxea, C; Boluda, JC; de Heredia, CD; Ferrá, C; González, M; Martín, C; Martinez, AM; Sanz, GF; Sanz, J; Sanz, MA; Serrano, D; Solano, C1
Bertz, H; Christopoulos, P; Finke, J; Ihorst, G; Marks, R; Wäsch, R1
Bernardo, ME; Bertaina, A; Caocci, G; Contoli, B; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Pagliara, D; Pinto, RM; Piras, E; Vacca, A; Zecca, M1
Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R1
Choudhary, D; Gupta, N; Handoo, A; Katewa, S; Kharya, G; Pavecha, P; Setia, R; Sharma, SK1
Bertz, H; Christopoulos, P; Finke, J; Marks, R; Schmoor, C; Wäsch, R; Waterhouse, M1
Andersson, BS; Bayraktar, UD; Boulad, F; Castro-Malaspina, HR; Champlin, RE; Chen, J; Chiattone, A; de Lima, M; Giralt, S; Jakubowski, AA; Kernan, NA; Maloy, M; O'Reilly, RJ; Papadopoulos, EB; Rondon, G; Saliba, RM1
Benesch, M; Brunner-Krainz, M; Lackner, H; Paschke, E; Plecko, B; Raicht, A; Schwinger, W; Seidel, M; Sovinz, P; Sperl, D; Strenger, V; Urban, C1
Dinur-Schejter, Y; Erlich, O; Gorelik, N; Krauss, AC; Porat, I; Stein, J; Stepensky, P; Weintraub, M; Yahel, A; Zaidman, I1
Angelucci, E; Baronciani, D; Culurgioni, F; Depau, C; Derudas, D; Latte, G; Palmas, A; Tandurella, I; Targhetta, C1
Barba, P; Bautista, G; Cabrera, JR; Duarte, R; Esquirol, A; Fores, R; García, I; García-Marco, JA; Heras, I; Marquez-Malaver, FJ; Martino, R; Parody, R; Regidor, C; Rovira, M; Saavedra, S; Sánchez-Ortega, I; Serrano, D; Sierra, J; Vazquez, L1
Champagne, C; Farrant, P; Taylor, M1
Arcese, W; Barba, P; Esquirol, A; Gayoso, J; Guidi, S; Martino, R; Montesinos, P; Moscardó, F; Parody, R; Picardi, A; Piñana, JL; Sanz, G; Sanz, J; Sanz, MA; Sierra, J; Solano, C; Terol, MJ1
Crazzolara, R; Haas, OA; Kager, L; Kropshofer, G; Matthes-Martin, S1
Abraham, A; Cluster, A; Delgado, D; Hulbert, ML; Jacobsohn, D; Kukadiya, D; Murray, L; Shenoy, S1
Anand, S; Chao, NJ; Corbet, K; Gasparetto, C; Horwitz, ME; Long, GD; Lopez, R; Morris, AK; Rizzieri, DA; Sarantopoulos, S; Sullivan, KM; Sung, AD; Thomas, S1
Bruno, B; Chalandon, Y; Charbonnier, A; Coiteux, V; Simon, N; Souchet, L; Taque, S; Vincent, L; Yakoub-Agha, I1
Bruce, K; Domm, J; Evans, M; Frangoul, H; Isbell, J1
Aljurf, M; Arcese, W; Beohou, E; Bonifazi, F; Bruno, B; Labopin, M; Lanza, F; Mohty, M; Nagler, A; Passweg, J; Pioltelli, P; Santarone, S; Saraceni, F; Savani, BN; Sociè, G; Stepensky, P; Yakoub-Agha, I1
Angelucci, E; Arcese, W; Baron, F; Benedetto, B; Blaise, D; Carella, MA; Giannotti, F; Labopin, M; Mohty, M; Nagler, A; Rambaldi, A; Rocha, V; Ruggeri, A; Saccardi, R; Santarone, S; Santasusana, JR; Sanz, J; Shouval, R; Sierra, J1
Alessandrino, EP; Bacigalupo, A; Bonifazi, F; Bosi, A; Bregante, S; Bruno, B; Carella, AM; Fanin, R; Finazzi, MC; Mammoliti, S; Masciulli, A; Messina, G; Milone, G; Narni, F; Patriarca, F; Pavoni, C; Rambaldi, A; Russo, D1
Basu, O; Döring, M; Ebinger, M; Gruhn, B; Handgretinger, R; Heinzelmann, F; Holzer, U; Lang, P; Paulsen, F; Teltschik, HM; Wegener, D; Weidner, N; Wittig, A; Zips, D1
Adaeva, R; Banet, A; Bastos, J; Battipaglia, G; Belhocine, R; Brissot, E; de Wyngaert, ZV; Duléry, R; Giannotti, F; Isnard, F; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Mohty, M; Paviglianiti, A; Rubio, MT; Ruggeri, A; Sestili, S; Vekhoff, A1
Beelen, D; Bochtler, T; Brecht, A; Bunjes, D; Eder, M; Einsele, H; Kröger, N; Labopin, M; Labussière-Wallet, H; Mohty, M; Nagler, A; Niederwieser, D; Saraceni, F; Savani, BN; Tischer, J1
Blaise, D; Bramanti, S; Calmels, B; Castagna, L; Chabannon, C; Charbonnier, A; Devillier, R; Faucher, C; Fürst, S; Granata, A; Harbi, S; Hospital, MA; Legrand, F; Lemarie, C; Lining, W; Maisano, V; Mokart, D; Pagliardini, T; Porta, MD; Rey, J; Saillard, C; Vey, N; Weiller, PJ1
Czyż, A; Danylesko, I; Fein, JA; Nagler, A; Shem Tov, N; Shimoni, A; Shouval, R; Sobas, M; Vega, Y; Yerushalmi, R1
Bednarski, JJ; Bhatt, ST; Hente, M; Murray, L; Schulz, G; Shenoy, S; Slater, A1
Altman Kohl, S; Even-Or, E; Molho-Pessach, V; Stepensky, P; Zaidman, I1
Briones, J; Brunet, S; Caballero, A; Esquirol, A; Garcia-Cadenas, I; Garrido, A; Granell, M; Martino, R; Moreno, C; Novelli, S; Querol, S; Saavedra, S; Sierra, J1
Angelucci, E; Bacigalupo, A; Bregante, S; Bruno, B; Chiusolo, P; Grazia, CD; Grisariu, S; Iori, AP; Mordini, N; Olivieri, A; Patriarca, F; Raiola, AM; Rambaldi, A; Sica, S; Sora, F; Terruzzi, E1
Bąbol-Pokora, K; Dąbrowska-Leonik, N; Frączkiewicz, J; Gul, K; Janeczko-Czarnecka, M; Kałwak, K; Martuszewski, A; Mielcarek-Siedziuk, M; Młynarski, W; Nowak, M; Paluszkiewicz, P; Salamonowicz-Bodzioch, M; Sierżęga-Staykov, K; Ussowicz, M; Wawrzyniak-Dzierżek, E; Wolska-Kuśnierz, B1
Al-Chami, F; Angelucci, E; Bazarbachi, A; Bonifazi, F; Bruno, B; Carella, AM; Castagna, L; El-Cheikh, J; Iori, AP; La Nasa, G; Labopin, M; Mohty, M; Nagler, A; Santarone, S; Savani, B1
Dandoy, CE; Davies, SM; El-Bietar, J; Grimley, MS; Khandelwal, P; Lane, A; Yeh, RF; Yu, L1
Bertz, H; Duque-Afonso, J; Finke, J; Ihorst, G; Köhler, T; Marks, R; Müller-Quernheim, J; Wäsch, R; Waterhouse, M; Yücel, M; Zeiser, R1
Barba, P; Bosch Vilaseca, A; Bosch, F; Esquirol, A; Fox, ML; García-Cadenas, I; Hernandez-Boluda, JC; Martino, R; Montoro, J; Ortí, G; Pérez, AM; Piñana, JL; Roldán, E; Saavedra, S; Salamero, O; Sanz, J; Sierra, J; Solano, C; Valcarcel, D; Villacampa, G1
Banet, A; Battipaglia, G; Belhocine, R; Bianchessi, A; Bonnin, A; Boussaroque, A; Brissot, E; Duléry, R; Favale, F; Hirsch, P; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Memoli, M; Mohty, M; Paviglianiti, A; Sestili, S; Van de Wyngaert, Z; Vekhoff, A1
Angelucci, E; Bazarbachi, A; Berceanu, A; Blaise, D; Bulabois, CE; Ceballos, P; El Cheikh, J; Forcade, E; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Rambaldi, A; Savani, B; Socié, G; Spyridonidis, A; Yakoub-Agha, I1
Kapoor, R; Rastogi, N; Yadav, SP1
Aleinikova, O; Ansari, M; Ariffin, H; Bader, P; Balduzzi, A; Bierings, M; Buechner, J; Burkhardt, B; Corbacioglu, S; Dalle, JH; Diaz-de-Heredia, C; Essa, M; Güngör, T; Ifversen, M; Lankester, A; Locatelli, F; Meisel, R; Peters, C; Pichler, H; Poetschger, U; Schrappe, M; Schultz, K; Sedlacek, P; Shaw, PJ; Staciuk, R; Stein, J; Svec, P; Toporski, J; Truong, TH; Vettenranta, K; von Stackelberg, A1
Angelucci, E; Arcese, W; Battipaglia, G; Blaise, D; Chalandon, Y; Chiusolo, P; Contentin, N; Czerw, T; de Wreede, LC; Fanin, R; Fox, ML; Hayden, P; Hernandez-Boluda, JC; Iori, AP; Kroger, N; Marotta, G; Mauff, K; McLornan, D; Mohty, M; Pioltelli, P; Rubio, MT; Santarone, S; Sever, M; Solano, C; Wendel, L; Yakoub-Agha, I1
Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S1
Cuesta, M; Esquirol, A; Ferrà, C; Garcia-Cadenas, I; Herruzo, B; Martino, R; Pascual, MJ; Pérez, A; Sierra, J; Torio, A; Torrent, A1
Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A1
Arpinati, M; Baronciani, D; Bernasconi, P; Bonifazi, F; Brunello, L; Bruno, B; Busca, A; Carella, AM; Carluccio, P; Casini, M; Chiusolo, P; Ciceri, F; Cilloni, D; Cupri, A; Di Grazia, C; Gheorghiu, A; Giglio, F; Girmenia, C; Grassi, A; Grillo, G; Iori, AP; Luppi, M; Martino, M; Masciulli, A; Musso, M; Nozzoli, C; Oldani, E; Onida, F; Palazzo, G; Parma, M; Patriarca, F; Pavoni, C; Peccatori, J; Picardi, A; Proia, A; Rambaldi, A; Sacchi, N; Santarone, S; Sorasio, R; Tringali, S; Vacca, A; Vallisa, D1
Abraham, A; Balasubramanian, P; Devasia, AJ; Fouzia, NA; George, B; Kavitha, ML; Korula, A; Kulkarni, UP; Lionel, S; Mathews, V; Pai, AA; Selvarajan, S; Sindhuvi, E; Srivastava, A1
Bertz, H; Bornhäuser, M; Burchert, A; Dreger, P; Finke, J; Glass, B; Grishina, O; Hegenbart, U; Kobbe, G; Reicherts, C; Schmoor, C; Schub, N; Sohlbach, K; Stelljes, M; Wagner-Drouet, EM1
Banet, A; Bazarbachi, A; Belhocine, R; Bonnin, A; Brissot, E; Duléry, R; El-Cheikh, J; Genthon, A; Labopin, M; Ledraa, T; Legrand, O; Malard, F; Memoli, M; Mohty, M; Sestili, S; Stocker, N; Van de Wyngaert, Z1
Gale, RP; Halahleh, KA; Ma'koseh, M; Muradi, I; Rimawi, DH; Sultan, I1
Cascio, E; Castillo, P; Farhadfar, N; Fort, J; Fraser, A; Horn, B; Lamba, J; Moore-Higgs, G; Slayton, W1
Bagnoli, F; Barbullushi, K; Bellani, V; Cassanello, G; Cavallaro, F; Galassi, G; Goldaniga, M; Onida, F; Saporiti, G; Serpenti, F1

Reviews

2 review(s) available for fludarabine and thiotepa

ArticleYear
Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma.
    Bone marrow transplantation, 2002, Volume: 30, Issue:12

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytokines; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunotherapy, Adoptive; Kidney Neoplasms; Melphalan; Multicenter Studies as Topic; Nephrectomy; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Survival Analysis; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine

2002
[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-T
    Bulletin du cancer, 2017, Volume: 104, Issue:12S

    Topics: Adult; Age Factors; Busulfan; Child; Comorbidity; Cyclophosphamide; Etoposide; France; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Liver Diseases; Melphalan; Obesity; Renal Insufficiency, Chronic; Societies, Medical; Surveys and Questionnaires; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2017

Trials

21 trial(s) available for fludarabine and thiotepa

ArticleYear
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
    Bone marrow transplantation, 2003, Volume: 32, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Combined Modality Therapy; Graft Survival; Graft vs Host Disease; Haplotypes; Hematologic Neoplasms; Histocompatibility; Humans; Middle Aged; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2003
Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.
    Bone marrow transplantation, 2004, Volume: 34, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Female; Graft Survival; Hematologic Neoplasms; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Survival Analysis; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2004
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
    Bone marrow transplantation, 2008, Volume: 41, Issue:10

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Vidarabine

2008
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
    British journal of haematology, 2008, Volume: 143, Issue:4

    Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2008
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
    Bone marrow transplantation, 2010, Volume: 45, Issue:3

    Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2010
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:5

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cord Blood Stem Cell Transplantation; Feasibility Studies; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Melphalan; Survival Rate; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult

2012
T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:6

    Topics: Adult; Antigens, CD34; Antilymphocyte Serum; Antineoplastic Agents; Disease-Free Survival; Ethnicity; Graft vs Host Disease; Histocompatibility Testing; HLA-C Antigens; Humans; Killer Cells, Natural; Leukemia, Myeloid; Lymphocyte Depletion; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Receptors, KIR; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation

2012
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.
    Bone marrow transplantation, 2012, Volume: 47, Issue:10

    Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Infant; Male; Middle Aged; Myeloablative Agonists; Neoplasm Staging; Recovery of Function; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine

2012
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
    Blood, 2012, Jul-12, Volume: 120, Issue:2

    Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Risk Factors; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2012
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2013
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
    Hematological oncology, 2016, Volume: 34, Issue:1

    Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2016
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
    European journal of haematology, 2016, Volume: 96, Issue:2

    Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Herpesvirus 4, Human; Hodgkin Disease; Humans; Infectious Mononucleosis; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine

2016
Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:9

    Topics: Alemtuzumab; Anemia, Sickle Cell; Calcineurin Inhibitors; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Hydroxyurea; Male; Melphalan; Mycophenolic Acid; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine

2017
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:5

    Topics: Adult; Blood Donors; Busulfan; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Prognosis; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine

2019
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:7

    Topics: Adolescent; Adult; Aged; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Mycophenolic Acid; Retrospective Studies; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine

2019
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:9

    Topics: Adult; Aged; Allografts; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine

2019
A single-center experience using alemtuzumab, fludarabine, melphalan, and thiotepa as conditioning for transplantation in pediatric patients with chronic granulomatous disease.
    Pediatric blood & cancer, 2020, Volume: 67, Issue:1

    Topics: Alemtuzumab; Child; Child, Preschool; Follow-Up Studies; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Infant; Melphalan; Myeloablative Agonists; Prognosis; Prospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2020
Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:5

    Topics: Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Vidarabine

2020
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 02-01, Volume: 39, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoradiotherapy; Child; Child, Preschool; Equivalence Trials as Topic; Etoposide; Female; Follow-Up Studies; Humans; International Agencies; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Thiotepa; Vidarabine; Whole-Body Irradiation

2021
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.
    Bone marrow transplantation, 2022, Volume: 57, Issue:6

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospective Studies; Recurrence; Thiotepa; Transplantation Conditioning; Vidarabine

2022
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
    Bone marrow transplantation, 2022, Volume: 57, Issue:11

    Topics: Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine

2022

Other Studies

49 other study(ies) available for fludarabine and thiotepa

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
    European journal of medicinal chemistry, 2015, Mar-06, Volume: 92

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3

2015
Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant.
    Annals of hematology, 2001, Volume: 80, Issue:9

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Graft Rejection; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Thiotepa; Transplantation, Homologous; Treatment Outcome; Vidarabine

2001
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
    Blood, 2002, Jan-01, Volume: 99, Issue:1

    Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Survival Rate; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2002
Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
    American journal of hematology, 2003, Volume: 72, Issue:2

    Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Graft Survival; Histiocytosis, Non-Langerhans-Cell; Humans; Infant; Melphalan; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2003
High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    The Korean journal of internal medicine, 2004, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2004
Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer.
    Bone marrow transplantation, 2006, Volume: 37, Issue:3

    Topics: Adult; Biomarkers, Tumor; Bone Marrow; Bone Marrow Neoplasms; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Female; Gene Expression Regulation, Neoplastic; Graft Survival; Graft vs Tumor Effect; Humans; Mammaglobin A; Middle Aged; Myeloablative Agonists; Neoplasm Proteins; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Uteroglobin; Vidarabine

2006
Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:4

    Topics: Adult; Aged; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Stem Cell Transplantation; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Parvovirus B19 pneumonia in a child undergoing allogeneic hematopoietic stem cell transplantation.
    Bone marrow transplantation, 2007, Volume: 40, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Combined Modality Therapy; Erythema Infectiosum; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Male; Parvovirus B19, Human; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiography, Thoracic; Recurrence; Thiotepa; Tomography, X-Ray Computed; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2007
Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning.
    Bone marrow transplantation, 2012, Volume: 47, Issue:3

    Topics: Adult; Animals; Antilymphocyte Serum; Carotid Arteries; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Probability; Rabbits; Retrospective Studies; Salvage Therapy; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine

2012
New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia.
    American journal of hematology, 2011, Volume: 86, Issue:7

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX.
    Clinical immunology (Orlando, Fla.), 2011, Volume: 141, Issue:2

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Cell Survival; Forkhead Transcription Factors; Genetic Diseases, X-Linked; Graft Enhancement, Immunologic; Graft Survival; Humans; Immunologic Deficiency Syndromes; Infant; Interleukin-2 Receptor alpha Subunit; Lymphocyte Depletion; Male; Melphalan; Point Mutation; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Thiotepa; Thymus Gland; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:9

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Carmustine; Central Nervous System; Cyclosporine; Drug Administration Schedule; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3

    Topics: Adolescent; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; India; Male; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML.
    Bone marrow transplantation, 2013, Volume: 48, Issue:7

    Topics: Adult; Aged; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Stem Cell Transplantation; Thiotepa; Time Factors; Transplantation Conditioning; Vidarabine

2013
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:6

    Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Thiotepa; Transplantation, Homologous; Treatment Outcome; Vidarabine

2013
Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome.
    Pediatric hematology and oncology, 2014, Volume: 31, Issue:8

    Topics: Antigens, CD19; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Chimerism; Drug-Related Side Effects and Adverse Reactions; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Depletion; Male; Mucopolysaccharidosis I; Peripheral Blood Stem Cell Transplantation; Quality of Life; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2014
Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:2

    Topics: Adolescent; Alkylating Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Retrospective Studies; Thiotepa; Vidarabine

2015
Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH).
    Transplant infectious disease : an official journal of the Transplantation Society, 2015, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Antigens, CD34; Bacterial Infections; Busulfan; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Multivariate Analysis; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Risk Factors; Severity of Illness Index; Thiotepa; Transplantation Conditioning; Vidarabine; Virus Diseases; Whole-Body Irradiation; Young Adult

2015
Permanent chemotherapy-induced nonscarring alopecia and premature ovarian failure.
    Clinical and experimental dermatology, 2015, Volume: 40, Issue:5

    Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Humans; Primary Ovarian Insufficiency; Thiotepa; Vidarabine

2015
Reduced-intensity conditioning and stem cell transplantation in infants with Diamond Blackfan anemia.
    Haematologica, 2017, Volume: 102, Issue:3

    Topics: Anemia, Diamond-Blackfan; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine

2017
Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:11

    Topics: Adult; Aged; Cord Blood Stem Cell Transplantation; Female; Humans; Male; Middle Aged; Thiotepa; Vidarabine; Whole-Body Irradiation; Young Adult

2017
Haploidentical hematopoietic stem cell transplant for patients with sickle cell disease using thiotepa, fludarabine, thymoglobulin, low dose cyclophosphamide, 200 cGy tbi and post transplant cyclophosphamide.
    Bone marrow transplantation, 2018, Volume: 53, Issue:5

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Antilymphocyte Serum; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Whole-Body Irradiation; Young Adult

2018
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
    American journal of hematology, 2018, Volume: 93, Issue:10

    Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Confidence Intervals; Cyclophosphamide; Disease-Free Survival; Drug Evaluation; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Retrospective Studies; Siblings; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult

2018
Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.
    Journal of hematology & oncology, 2018, 08-30, Volume: 11, Issue:1

    Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Young Adult

2018
Immunosuppressive Total Nodal Irradiation-Based Reconditioning Regimens After Graft Rejection or Graft Failure in Pediatric Patients Treated With Myeloablative Allogeneic Hematopoietic Cell Transplantation.
    International journal of radiation oncology, biology, physics, 2019, 05-01, Volume: 104, Issue:1

    Topics: Adolescent; Allografts; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Child, Preschool; Follow-Up Studies; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunosuppression Therapy; Kaplan-Meier Estimate; Lymphatic Irradiation; Muromonab-CD3; Myeloablative Agonists; Radiotherapy Dosage; Retreatment; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult

2019
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and
    Journal of hematology & oncology, 2019, 04-25, Volume: 12, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult

2019
Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.
    Bone marrow transplantation, 2020, Volume: 55, Issue:1

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2020
Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation.
    Pediatric transplantation, 2020, Volume: 24, Issue:1

    Topics: Busulfan; Child; Child, Preschool; Drug Eruptions; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Prognosis; Prospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2020
When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (t
    Annals of hematology, 2020, Volume: 99, Issue:1

    Topics: Adult; Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Female; Hematologic Neoplasms; HLA Antigens; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2020
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:4

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2020
Successful Allogeneic Stem Cell Transplantation in Nuclear Factor-Kappa B Essential Modulator Deficiency Syndrome After Treosulfan-Based Conditioning: A Case Report.
    Transplantation proceedings, 2020, Volume: 52, Issue:2

    Topics: Antilymphocyte Serum; Busulfan; Ectodermal Dysplasia; Hematopoietic Stem Cell Transplantation; Humans; I-kappa B Kinase; Immunologic Deficiency Syndromes; Infant; Male; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2020
Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
    Transplantation, 2021, 04-01, Volume: 105, Issue:4

    Topics: Abatacept; Adolescent; beta-Thalassemia; Busulfan; Calcineurin Inhibitors; Child; Child, Preschool; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Retrospective Studies; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2021
Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation.
    Bone marrow transplantation, 2021, Volume: 56, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2021
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:8

    Topics: Busulfan; Feasibility Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Sirolimus; Tacrolimus; Thiotepa; Transplantation Conditioning; Vidarabine

2020
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:2

    Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Primary Myelofibrosis; Thiotepa; Transplantation Conditioning; Vidarabine

2021
Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
    Bone marrow transplantation, 2021, Volume: 56, Issue:3

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Vidarabine

2021
Haploidentical Stem Cell Transplant With Post Transplant Cyclophosphamide for Chronic Granulomatous Disease With Thiotepa, Busulfan, and Fludarabine as Conditioning.
    Journal of pediatric hematology/oncology, 2021, 05-01, Volume: 43, Issue:4

    Topics: Antineoplastic Agents; Busulfan; Child, Preschool; Cyclophosphamide; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine

2021
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
    Bone marrow transplantation, 2021, Volume: 56, Issue:7

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasms; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2021
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.
    Journal of pediatric hematology/oncology, 2021, Oct-01, Volume: 43, Issue:7

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2021
Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide.
    Transplantation and cellular therapy, 2021, Volume: 27, Issue:7

    Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Thiotepa; Transplantation Conditioning; Vidarabine

2021
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W
    Bone marrow transplantation, 2022, Volume: 57, Issue:3

    Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2022
Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:7

    Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Humans; Infant; Male; Retrospective Studies; Thiotepa; Vidarabine; Young Adult

2022
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
    Bone marrow transplantation, 2023, Volume: 58, Issue:1

    Topics: Adolescent; Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult

2023
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
    Acta haematologica, 2023, Volume: 146, Issue:1

    Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2023
Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:7

    Topics: Anemia, Sickle Cell; Busulfan; Child; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Thiotepa

2023
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
    Bone marrow transplantation, 2023, Volume: 58, Issue:9

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thiotepa; Transplantation Conditioning; Vidarabine

2023